Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III open-label study of Kedrion IVIg 10% in pediatric primary immunodeficiency
2020-001496-32Phase 3Completed
- Sponsor
- Kedrion Biopharma
- Start
- Jul 2020
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of immune globulin intravenous (human) in Immunogenetic disorder, sponsored by Kedrion Biopharma. Primary endpoint: Incidence rate of acute serious bacterial infections. Started Jul 2020; status: completed.
02
Drugs
immune globulin intravenous (human)
03
Conditions
Immunogenetic disorder
Beyond the preview
Go deeper on 2020-001496-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001496-32.